Aradigm loses CEO, CMO and CFO following regulatory disaster; Omeros shares go up on positive results for blood clot treatment
→ As Aradigm $ARDM contends with the aftermath of a disastrous regulatory journey, it has let go of three of its top executives in an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
